APLS Live signals | Maximize Profits with Getagraph.com

BUY 2922 min ago

@ $41.18

Issued: 17 May 2024 @ 14:45

Return: 0.33%

Previous signal: May 17 - 13:08

Previous signal: Sell

Return: -1.80 %

Live Chart Being Loaded With Signals

Commentary (17 May 2024 @ 16:00):

Stats
Today's Volume	857 458
Average Volume	1.45M
Market Cap	5.01B
EPS	$0 ( 2024-05-07 )
Next earnings date	( $-0.330 ) 2024-07-29
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-12.04
ATR14	$1.256 (3.04%)

Insider Trading

Date	Person	Action	Amount	type
2024-05-08	Deschatelets Pascal	Buy	78 907	Common Stock
2024-05-08	Deschatelets Pascal	Sell	56 335	Common Stock
2024-05-08	Deschatelets Pascal	Sell	22 472	Common Stock
2024-05-08	Deschatelets Pascal	Sell	100	Common Stock
2024-05-08	Deschatelets Pascal	Sell	78 907	Stock Option (Right to Buy)

INSIDER POWER
-8.61
Last 100 transactions
Buy: 974 008 \| Sell: 1 114 069

Volume Correlation

Long: -0.17 (neutral)

Short: -0.56 (weak negative)

Signal:(48) Neutral

Apellis Pharmaceuticals Correlation

10 Most Positive Correlations
DLHC	0.939
MPAA	0.932
APDN	0.927
MBIO	0.924
ARKO	0.92
GLPG	0.916
TOI	0.914
SSYS	0.913
ASNS	0.913
SAGE	0.91

10 Most Negative Correlations
AEYE	-0.929
VCTR	-0.928
BNTC	-0.927
SMTC	-0.927
VITL	-0.923
KALU	-0.922
SLAM	-0.92
NKTR	-0.917
CGBD	-0.917
JAN	-0.916

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Apellis Pharmaceuticals Correlation - Currency/Commodity

-0.48
( neutral )

-0.42
( neutral )

0.00
( neutral )

-0.39
( neutral )

-0.25
( neutral )

0.34
( neutral )

Apellis Pharmaceuticals Financials

Annual	2023
Revenue:	$396.59M
Gross Profit:	$336.38M (84.82 %)
EPS:	$-4.45

FY	2023
Revenue:	$396.59M
Gross Profit:	$336.38M (84.82 %)
EPS:	$-4.45

FY	2022
Revenue:	$75.42M
Gross Profit:	$69.79M (92.53 %)
EPS:	$-6.15

FY	2021
Revenue:	$66.56M
Gross Profit:	$61.36M (92.19 %)
EPS:	$-8.84

Financial Reports:

No articles found.

Apellis Pharmaceuticals Options Data

Calls

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Puts

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Apellis Pharmaceuticals

Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. The company's lead product candidate is pegcetacoplan that is in Phase III clinical trials for the treatment of geographic atrophy (GA) in age-related macular degeneration and paroxysmal nocturnal hemoglobinuria (PNH) diseases. It also develops EMPAVELI (systemic pegcetacoplan) for the treatment of cold agglutinin disease (CAD), and hematopoietic stem cell transplantation-associated thrombotic microangiopathy (HSCT-TMA) in hematology; C3 glomerulopathy (C3G), and immune complex membranoproliferative glomerulonephritis (IC-MPGN) in nephrology; and amyotrophic lateral sclerosis (ALS) in neurology. In addition, the company develops APL-2006, a bispecific C3 and VEGF inhibitor for treating complement-mediated disorders; APL-1030, a C3 inhibitor for the treatment of multiple neurodegenerative diseases; and the combination of EMPAVELI and a small interfering RNA, or siRNA for reducing the production of C3 proteins by the liver. It has a collaboration and license agreement with Swedish Orphan Biovitrum AB (publ) to co-develop pegcetacoplan; and a research collaboration with Beam Therapeutics Inc. focused on the use of Beam's base editing technology to discover new treatments for complement-driven diseases. Apellis Pharmaceuticals, Inc. was incorporated in 2009 and is based in Waltham, Massachusetts.